Welcome to Ventana Medical Systems – Newest Blog Sponsor

| September 9, 2009

 

Th_0701vsd_spotlight01 I am pleased to welcome Ventana Medical Systems, Inc. as the newest educational sponsor to the blog.  Many thanks to Ventana for their generous support to help provide an ongoing blog environment for the digital pathology and laboratory community.

Ventana Medical Systems, Inc. is committed to digital pathology image analysis and is a recognized leader in cancer diagnostic research and development of instrument and reagent systems. 

 

The Ventana Image Analysis System (VIAS) meets ASCO/CAP guidelines for HER-2/neu digital image analysis. This flexible software tools aid pathologists in visualization, segmentation, and interpretation of cancer cell images while increasing confidence and reproducibility in breast panel scoring.

 

Ventana is the world’s leading supplier of automated diagnostic systems to the anatomical pathology market. Their instrument and reagent systems are used in clinical histology, cytology and drug discovery laboratories around the globe. Through automation and systems integration, Ventana is standardizing and optimizing the slide staining process, thereby helping pathologists recommend treatment solutions that deliver superior patient care.

Customers include hospital-based histology labs, independent reference labs, medical research centers and drug discovery laboratories of the largest pharmaceutical and biotechnology companies in the world.

 
To learn more, visit www.ventanamed.com
 


Category: Digital Pathology News, Histology, Image Analysis, Vendor products

Comments (1)

Trackback URL | Comments RSS Feed

  1. Venetia Sarode says:

    we have used the VIAS for almost a year now and we are not happy with the Her2neu interpretation by this sytstem. We’ve had several instances where the Her2 was read as 3+ by the machine and not amplified by FISH. The false positives are very concerning to me. We do perform Her2 FISH on all of our 2 and 3+ Her2 IHC. I would like to know if anyone else had similar experience.